SpotitEarly, a biotech startup from Israel, just launched in the U.S. with a bold idea—and $20.3 million in funding. Its approach? A home breath test analyzed by trained dogs and AI to detect early-stage cancers. Backed by published studies and a 94% accuracy rate, the test targets breast, lung, prostate, and colorectal cancers.
With U.S. screening rates still alarmingly low, SpotitEarly believes it’s not just disrupting diagnostics—it’s rewriting the rules of early detection.